罕见 GLP1R 变异与司美格鲁肽减重效果减弱相关,替尔泊肽不受影响
Rare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide
一项大型真实世界基因组研究发现,编码 GLP-1 受体的基因中存在罕见破坏性变异的个体,使用司美格鲁肽(semaglutide)后的减重效果较弱,而改用同时靶向 GIP 受体的替尔泊肽(tirzepatide)后减重效果未见显著差异。
- Research Briefing
- Published: 13 November 2026
Nature Metabolism (2026) Cite this article
In a large, real-world genomic study, rare damaging variants in the gene encoding the glucagon-like peptide 1 (GLP1) receptor blunted weight loss in people taking semaglutide but had no significant effect on weight loss with tirzepatide, a drug that also targets the glucose-dependent insulinotropic polypeptide (GIP) receptor.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
32.70 € / 30 days cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
111.21 € per year only 9.27 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Additional access options:

References
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021). A pivotal trial that established the efficacy of semaglutide in weight loss.
Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022). A pivotal trial that established the efficacy of tirzepatide in weight loss.
Willard, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5, e140532 (2020). A paper that describes the dual-receptor pharmacology of tirzepatide, which might preserve metabolic control when responsiveness to either receptor varies.
Gao, W. et al. Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity. Nat. Metab. 5, 1673–1684 (2023). A paper providing evidence that rare GLP1R variants have functional consequences and metabolic associations.
Su, Q. J. et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature 653, 770–775 (2026). A study that identified a common GLP1R variant associated with greater weight loss.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Levy, M. E. et al. Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide. Nat. Metab. https://doi.org/10.1038/s42255-026-01656-z (2026).
M.E.L. and E.T.C. used Claude (Anthropic) to help prepare their contribution to the Research Briefing.
About this article
Cite this article
Rare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01661-2
Published: 13 November 2026
Version of record: 13 November 2026
DOI: https://doi.org/10.1038/s42255-026-01661-2
来源:Nature 健康护理主题 · nature.com